Glicisa-M 2 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. This dual mechanism provides effective glycemic control by addressing both insulin secretion and insulin resistance. Glicisa-M 2 Forte Tablet PR is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy after monotherapy failure. The extended-release formulation ensures sustained plasma drug levels, improving patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. It is essential to monitor renal function prior to and during treatment due to the risk of lactic acidosis associated with Metformin. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to either component. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and weight gain. Regular blood glucose monitoring and periodic assessment of renal and hepatic function are recommended to optimize therapy and minimize risks. Glicisa-M 2 Forte Tablet PR should be used under medical supervision with appropriate lifestyle modifications.